Drug · Small Molecule

Cisplatin

CI-DRUG-00000157Explore in graph →NCIt C376 CHEMBL11359 CIViC Approved

Regulatory

Approvals (16)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory13 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION BP (DIN 02536285) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 23, 2024	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02403188) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 29, 2013	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION, MYLAN STD. (DIN 02396890) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 6, 2016

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	606	295	672	2,480	16	CA, US	Dec 19, 1978	1988-04
Malignant Bladder Neoplasm	Approved	Phase 3	27	10	17	93	1	US	Dec 19, 1978	1995-05
Malignant Lung Neoplasm	Phase4	Phase 4	144	58	173	557	0	—	—	1993-01
Malignant Cervical Neoplasm	Phase4	Phase 4	38	18	51	160	0

Curated evidence

Clinical evidence (78)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 51–78 of 78 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ACTL6A Overexpression1
Cisplatin	Malignant Ovarian Neoplasm

Clinical trials

Trials with this intervention (2,506)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 2,351–2,400 of 2,506 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01142414	Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence	withdrawn	Phase 3	0	European Organisation for Research and Treatment of Cancer - EORTCNETWORK	0	Jan 16, 2012	clinicaltrials
NCT00215995	Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Molecule

Record

Kind: Small Molecule
Mechanism: DNA inhibitor
UNII: Q20Q21Q62J
Aliases: Abiplatin, Blastolem, Briplatin, CDDP, CIS-DDP, Cis-diamminedichloridoplatinum, Cis-diammine-dichloroplatinum, Cis-diamminedichloroplatinum, Cis-diamminedichloroplatinum(ii), Cis-diamminedichloro Platinum (II), Cis-dichloroammine Platinum (II), Cismaplat, Cis-platin, Cisplatin, Cisplatina, CISPLATIN COMPONENT OF INT-230-6, CISPLATIN COMPONENT OF INT230-6, Cisplatine, CISPLATIN INJECTION, MYLAN STD., Cisplatino, Cis-platinous Diamine Dichloride, Cis-platinum, Cisplatinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP … (+27)

Data updated 19 hours agoSource updated unknown

Identifiers

Codes (27)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XA01	CISPLATIN
DIN (Health Canada)	00644293

BRCA1 Mutation3
Cisplatin + OxaliplatinSubstitutes	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID5915 Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC) PMID 25072261 · Golan et al., 2014 · Open in CIViC	civic
Cisplatin + Gemcitabine + VeliparibCombination	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID5932 In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-p… (full text at CIViC) PMID 29338080 · O'Reilly et al., 2018 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1684 In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC) PMID 25847936 · Isakoff et al., 2015 · Open in CIViC	civic

BRCA2 Mutation2
Cisplatin + Gemcitabine + VeliparibCombination	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID5933 In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-p… (full text at CIViC) PMID 29338080 · O'Reilly et al., 2018 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1685 In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC) PMID 25847936 · Isakoff et al., 2015 · Open in CIViC	civic